SIRINGO, MARCO
 Distribuzione geografica
Continente #
EU - Europa 512
NA - Nord America 165
AS - Asia 148
OC - Oceania 4
AF - Africa 3
SA - Sud America 2
Totale 834
Nazione #
IT - Italia 378
US - Stati Uniti d'America 157
SG - Singapore 70
IN - India 24
ES - Italia 22
FI - Finlandia 18
KR - Corea 18
RU - Federazione Russa 18
NL - Olanda 16
DE - Germania 12
GB - Regno Unito 11
FR - Francia 10
SE - Svezia 9
CN - Cina 8
BG - Bulgaria 6
CA - Canada 5
CH - Svizzera 5
ID - Indonesia 5
AU - Australia 4
IE - Irlanda 3
IL - Israele 3
IR - Iran 3
MX - Messico 3
BE - Belgio 2
HK - Hong Kong 2
JO - Giordania 2
JP - Giappone 2
MO - Macao, regione amministrativa speciale della Cina 2
MY - Malesia 2
PH - Filippine 2
PK - Pakistan 2
ZA - Sudafrica 2
AR - Argentina 1
GR - Grecia 1
GY - Guiana 1
HU - Ungheria 1
KG - Kirghizistan 1
TG - Togo 1
TR - Turchia 1
UZ - Uzbekistan 1
Totale 834
Città #
Rome 146
Singapore 47
Milan 30
Ashburn 16
Helsinki 16
Santa Clara 16
Perugia 15
Florence 14
Fairfield 12
Barcelona 11
Latina 9
Madrid 9
Naples 9
Salt Lake City 8
New York 6
Sofia 6
Boardman 5
Cassano Allo Ionio 5
Jakarta 5
Moscow 5
Pomezia 5
Boston 4
Chandler 4
Genoa 4
Goyang-si 4
Hyderabad 4
Imperia 4
Princeton 4
Albano Laziale 3
Bengaluru 3
Dongjak-gu 3
Dublin 3
Faenza 3
Geneva 3
Paris 3
Seattle 3
Tel Aviv 3
Wilmington 3
Amman 2
Amsterdam 2
Artena 2
Bergamo 2
Bernareggio 2
Bhubaneswar 2
Boydton 2
Brighton 2
Brisbane 2
Brugherio 2
Catania 2
Changsha 2
Chicago 2
Columbus 2
Corato 2
Frankfurt am Main 2
Imola 2
Incheon 2
Jena 2
Johannesburg 2
Kolkata 2
Lahore 2
Lappeenranta 2
Locate di Triulzi 2
Los Angeles 2
Macao 2
Manresa 2
Mapo-gu 2
Messina 2
Mexico City 2
Millbury 2
Misterbianco 2
Montreal 2
Monza 2
Morlupo 2
Newton 2
Nuremberg 2
Philadelphia 2
Portland 2
Ravenna 2
Roanoke 2
Rotterdam 2
Ruislip 2
Santa Maria a Vico 2
Schlieren 2
Seoul 2
Stockholm 2
Thiene 2
Tokyo 2
Toronto 2
Turin 2
Vallefoglia 2
Venice 2
Washington 2
Willingboro 2
Wilmslow 2
Yubileyny 2
Andover 1
Ankara 1
Arezzo 1
Austin 1
Beauharnois 1
Totale 572
Nome #
Circulating Cancer-Associated Macrophage-like Cells as a Blood-Based Biomarker of Response to Immune Checkpoint Inhibitors 103
Selective Internal Radiation Therapy (SIRT): a new emerging role for Breast Cancer Liver Metastases 86
Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study 79
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 72
CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line 69
Circulating CD137+T cells as an immune biomarker for response to anti-PD1 immunotherapy in NSCLC patients 60
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 43
Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer 42
Treg/CD137+ T cell balance as a novel biomarker of survival in advanced non-addicted NSCLC patients treated with immunotherapy as first-line 40
Co-Occurrence of ALK rearrangement and KRAS G12C mutation in NSCLC. Report of two cases 32
Circulating CD137+ T cell subsets and MDCSs as immune biomarkers for response to anti-PD1 immunotherapy in NSCLC patients 32
Evaluation of efficacy of ALK inhibitors according to body mass index in ALK rearranged NSCLC patients—A retrospective observational study 29
ADJUVANT TREATMENT IN ELDERLY CANCER PATIENTS: A MULTICENTER REAL-LIFE EXPERIENCE 28
Blood Extracellular Vesicles beyond Circulating Tumour Cells: A Valuable Risk Stratification Biomarker in High-Risk Non-Muscle-Invasive Bladder Cancer Patients 19
EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO) 18
Clinical utility of combined plasma and tissue NGS in patients with advanced, treatment-naïve, Non-small Cell Lung Cancer 17
null 17
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy 15
Clinical Utility of Combined Plasma and Tissue NGS in Patients With Newly Diagnosed Advanced Non-Small Cell Lung Cancer 15
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 15
Adjuvant treatment in elderly cancer patients: a multicenter real-life experience 14
Comparison between liquid biopsy and tissue NGS in two cohorts of advanced NSCLC 14
Anti-PD1 therapies induce an early expansion of Ki67+CD8+ T cells in metastatic non-oncogene addicted NSCLC patients 11
Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease 8
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 6
Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer 6
Clinical Utility of Combined Tissue and Plasma Next-Generation Sequencing in Patients with Advanced, Treatment-Naïve, Non-Small-Cell Lung Cancer 3
Totale 893
Categoria #
all - tutte 3.931
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.931


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202 0 0 0 0 0 0 0 0 0 0 0 2
2020/20218 0 0 0 0 0 0 0 0 0 0 0 8
2021/202248 2 0 1 1 2 2 4 1 10 1 19 5
2022/202359 8 4 2 5 4 6 3 10 0 2 4 11
2023/2024416 13 16 9 23 58 71 31 19 2 50 58 66
2024/2025360 55 46 31 53 84 54 37 0 0 0 0 0
Totale 893